Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (815)	8/30/2001 9:46:43 AM
From: tuck	Read Replies (1) \| Respond to of 1784

>>BILLERICA, Mass.--(BW HealthWire)--Aug. 30, 2001--Bruker Daltonics Inc. (NASDAQ: BDAL - news) and Thermo Finnigan Corporation, a business of Thermo Electron Corporation (NYSE: TMO - news), today announced a comprehensive settlement agreement in their litigation in the U.S. and Europe. The worldwide settlement agreement announced today provides for the dismissal of all pending suits, the waiving of all damages, and a framework of licensing and arbitration for potential future patent disputes between the companies in the field of ion trap mass spectrometry (ITMS). The settlement allows both companies, as well as their distributors and Bruker Daltonics' strategic partner Agilent, to sell their unmodified ITMS systems again in Germany effective immediately. Bruker Daltonics and Thermo Finnigan also have cross-licensed each other worldwide under all patents in suit for all ITMS fields of use, except gas chromatography (GC) coupled to ITMS. ``We are pleased that we have been able to settle our differences,'' said Frank H. Laukien, Ph.D., President and CEO of Bruker Daltonics. ``First and foremost, our customers will benefit from having competitive choices without concerns about patent infringement. Moreover, we believe that this will even further enhance the significant role of ion trap mass spectrometry in proteomics and other applications. Finally, both companies will be able to spend less money on litigation, and instead can focus more resources on R&D, new life-science applications, and customer support.'' << snip Cheers, Tuck